ICOS Corp., a Bothell, Wash.-based company, Tuesday said it entered two collaboration agreements.
In one deal, with Seattle Genetics Inc., also of Bothell, Wash., ICOS has agreed to perform process development, scale-up and GMP manufacturing on SGN-15, Seattles lead antibody-drug conjugate. SGN-15 is in Phase II trials for the treatment of breast, colon and prostate cancers. Financial terms were not disclosed.
The two companies also are working together on the development of SGN-30, a Seattle Genetics product expected to enter clinical trials next year. Seattle Genetics said it has relocated its corporate office and laboratory space to a larger facility located a short distance from the former site in Bothell.
The second ICOS deal is with Array BioPharma Inc., of Boulder, Colo., to discover and develop small molecule drugs directed at disease targets containing the I-domain allosteric site structural motif.
ICOS has identified structural features of proteins containing the IDAS motif that will be exploited by Arrays chemists. Terms call for ICOS to provide Array with research funding for two years while scientists from both companies collaborate in all aspects of lead generation and lead optimization.
ICOS, which has its own trials under way in sexual dysfunction, severe sepsis and pulmonary arterial hypertension, also will be responsible for clinical development and commercialization. Array will receive milestones and royalties. Kim Coghill